Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

Bellentani, 2009, Epidemiology and natural history of nonalcoholic fatty liver disease (NAFLD), Ann Hepatol, 8, S4, 10.1016/S1665-2681(19)31820-4 Caldwell, 1999, Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease, Hepatology, 29, 664, 10.1002/hep.510290347 Mendes, 2012, Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 10, 1028, 10.1016/j.cgh.2012.05.008 Bhala, 2011, The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study, Hepatology, 54, 1208, 10.1002/hep.24491 Baffy, 2012, Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace, J Hepatol, 56, 1384, 10.1016/j.jhep.2011.10.027 Agopian, 2012, Liver transplantation for nonalcoholic steatohepatitis: the new epidemic, Ann Surg, 256, 624, 10.1097/SLA.0b013e31826b4b7e Adams, 2005, The natural history of nonalcoholic fatty liver disease: a population-based cohort study, Gastroenterology, 129, 113, 10.1053/j.gastro.2005.04.014 Dam-Larsen, 2009, Final results of a long-term, clinical follow-up in fatty liver patients, Scand J Gastroenterol, 44, 1236, 10.1080/00365520903171284 Ekstedt, 2006, Long-term follow-up of patients with NAFLD and elevated liver enzymes, Hepatology, 44, 865, 10.1002/hep.21327 Younossi, 2011, Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality, Hepatology, 53, 1874, 10.1002/hep.24268 Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 Brunt, 2011, Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings, Hepatology, 53, 810, 10.1002/hep.24127 Brunt, 2011, Misuse of scoring systems, Hepatology, 54, 369, 10.1002/hep.24347 Angulo, 2011, Diagnosing steatohepatitis and predicting liver-related mortality in patients with NAFLD: two distinct concepts, Hepatology, 53, 1792, 10.1002/hep.24403 Brunt, 2009, Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network, Hepatology, 49, 809, 10.1002/hep.22724 Rakha, 2010, Portal inflammation is associated with advanced histological changes in alcoholic and non-alcoholic fatty liver disease, J Clin Pathol, 63, 790, 10.1136/jcp.2010.079145 Non-competing continuation progress report (PHS 2590). US Department of Health and Human Services Public Health Service, 2014. Available: http://grants.nih.gov/grants/funding/2590/phs2590.pdf. Accessed: March 6, 2015. de Franchis, 2010, Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension, J Hepatol, 53, 762, 10.1016/j.jhep.2010.06.004 Bruix, 2011, Management of hepatocellular carcinoma: an update, Hepatology, 53, 1020, 10.1002/hep.24199 Sanyal, 2011, Endpoints and clinical trial design for nonalcoholic steatohepatitis, Hepatology, 54, 344, 10.1002/hep.24376 Brunt, 2012, Histologic predictors of improvement in fibrosis in NASH: results from the Clinical Research Network PIVENS trial, Hepatology, 56, 887A Angulo, 2011, Clinical trials: trial design in NASH—realities and challenges, Nat Rev Gastroenterol Hepatol, 8, 424, 10.1038/nrgastro.2011.125 Sanyal, 2010, Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis, N Engl J Med, 362, 1675, 10.1056/NEJMoa0907929 Brunt, 2013, Progression to bridging fibrosis in non-alcoholic fatty liver disease over 4 years in the NASH CRN, Hepatology, 58, 495A Kleiner, 2014, Fibrosis progression in adult non-alcoholic fatty liver disease: association with severity of histological features, Mod Pathol, 27, 423A Bedossa, 2014, Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease, Hepatology, 60, 565, 10.1002/hep.27173